KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE.

Cynthia Levy, Christopher L Bowlus, Eric Lawitz, Nuno Antunes, Benjamin Miller, Jianfen Shu, Claudia O Zein, Kris V Kowdley

Liver Int 46(5) e70630

PMID41937506
PMCIDPMC13051278
DOI10.1111/liv.70630
发表日期2026-04-06
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:森林图/亚组分析图;FIGURE 3:非 KM 图;FIGURE 4:森林图/亚组分析图;FIGURE 5:AI 判定为 other。
摘要

摘要

BACKGROUND & AIMS: Baseline alkaline phosphatase (ALP) levels can influence the likelihood of achieving dichotomous biochemical response criteria in primary biliary cholangitis (PBC). This concept was explored using Week 52 data from the phase III ELATIVE trial (NCT04526665), which assessed elafibranor, a peroxisome proliferator-activated receptor α/δ agonist approved as a second-line treatment for PBC. METHODS: Patients were grouped by baseline ALP. Outcomes assessed: biochemical response, ALP normalization, ALP change from baseline (CfB), transplant-free survival (using GLOBE score). RESULTS: At Week 52, biochemical response was achieved across all subgroups receiving elafibranor (≤ 2× upper limit of normal [ULN]: 86.7%, > 2-≤ 2.5× ULN: 80.0%, > 2.5-≤ 3× ULN: 52.0%, > 3-≤ 4× ULN: 22.2%, > 4× ULN: 18.8%), and one subgroup receiving placebo (≤ 2× ULN: 13.3%). ALP normalization occurred only with elafibranor (≤ 2× ULN: 53.3%, > 2-≤ 2.5× ULN: 12.0%, > 2.5-≤ 3× ULN: 12.0%, > 4× ULN: 12.5%). Mean ALP reductions were consistent across subgroups receiving elafibranor (overall CfB: -38.9%). Patients receiving elafibranor, regardless of biochemical response, had similar reductions in risk of liver transplant and/or liver-related mortality within 15 years (-4.0% to -4.5%); among patients receiving placebo, reduced risk was only predicted in responders (-1.5%). CONCLUSIONS: In ELATIVE, lower baseline ALP correlated with higher biochemical response and ALP normalization rates with elafibranor. However, among patients receiving elafibranor, relative reductions in risk scores and ALP were consistent regardless of biochemical response and pre-treatment ALP, indicating treatment benefit. Similar biochemical benefits were not observed among patients receiving placebo. These results support evaluating continuous measures and prognostic scores alongside dichotomous criteria to comprehensively assess efficacy. TRIAL REGISTRATION: NCT04526665.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Proportion of patients in each ALP baseline subgroup across treatment arms. ALP: Alkaline phosphatase; ULN: Upper limit of normal.
非 KM Figure
FIGURE 2Proportion of patients achieving biochemical response † and ALP normalization at Week 52, stratified by baseline ALP level. Percentages are expressed as a percentage of patients within the respective baseline ALP subgroups (All: Elafibranor n = 108, placebo n = 53; ALP ≤ 2× ULN: Elafibranor n = 15, placebo n = 15; ALP > 2–≤ 2.5× ULN: Elafibranor n = 25, placebo n = 14; ALP > 2.5–≤ 3× ULN: Elafibranor n = 25, placebo n = 4; ALP > 3–≤ 4× ULN: Elafibranor n = 27, placebo n = 9; ALP > 4× ULN: Elafibranor n = 16, placebo n = 11). † According to the primary endpoint. ALP: Alkaline phosphatase; ULN: Upper limit of normal.
非 KM Figure
FIGURE 3Mean percentage change from baseline in ALP at Week 52, stratified by baseline ALP level. ALP: Alkaline phosphatase; SD: Standard deviation; ULN: Upper limit of normal.
非 KM Figure
FIGURE 4Waterfall plot of percentage change from baseline to Week 52 in ALP in patients receiving elafibranor stratified by baseline ALP levels. Dotted lines represent the mean percentage change from baseline in each baseline ALP subgroup. ALP: Alkaline phosphatase; ULN: Upper limit of normal.
非 KM Figure
FIGURE 5Risk change in estimated transplant‐free survival rates based on GLOBE score between Week 52 and baseline, stratified by achievement of biochemical response according to the primary endpoint † . † Defined according to the POISE criteria (ALP < 1.67× ULN, with ≥ 15% reduction from baseline, and TB≤ULN). TB ULN value was 1.2 mg/dL in females and males; ALP ULN values were 104 U/L in females and 129 U/L in males. ALP: Alkaline phosphatase; TB: Total bilirubin; ULN: Upper limit of normal.
非 KM Figure